Navigation Links
Genzyme Reports Strong First-Quarter Growth
Date:4/23/2008

a and an established global regulatory and commercial

organization.

-- Sales of Aldurazyme(R) (laronidase) increased 38 percent to $37.0

million in the first quarter, compared with $26.8 million in the same

quarter a year ago. Genzyme now records sales of Aldurazyme on its top

line and makes tiered payments to BioMarin Pharmaceutical Inc. on

worldwide product sales under a restructured agreement between the

companies.

-- Sales of Thyrogen(R) (thyrotropin alfa for injection) grew 28 percent

in the first quarter to $33.8 million from $26.3 million, reflecting

ongoing improvement in thyroid cancer detection and well-established

treatment guidelines. The use of Thyrogen in ablation procedures is

also contributing to the product's growth, following the December 2007

U.S. approval for this indication.

-- Within the Renal business, sales of sevelamer therapies Renagel(R)

(sevelamer hydrochloride) and Renvela grew 23 percent to $168.7 million

from $137.4 million in the first quarter last year. In March, Genzyme

launched Renvela in the United States, where the company is engaged in

active discussions with the FDA to expand the product's labeling to

include chronic kidney disease patients with hyperphosphatemia who are

not on dialysis. The three companies that currently market phosphate

binders are working collaboratively to provide the FDA with information

that will help the agency determine the appropriate treatment paradigm

for these patients. Genzyme anticipates that the Renvela label

expansion will take place at the latest by the middle of 2009. Genzyme

has also filed for European approval for Renvela in both the dialysis

and chronic kidney disease indications.

-- Within the Transplant business, first-quarter sales of Thymoglobulin(R)
'/>"/>

SOURCE Genzyme Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related biology technology :

1. Genzyme to Build New R&D Center in Beijing
2. Genzyme Provides Update on Myozyme(R) Manufacturing
3. Genzyme Withdraws Bioenvisions European Filing of Evoltra(R) in Elderly AML Patients
4. Genzyme Launches Renvela(R) in the U.S. for Dialysis Patients
5. Genzyme and Isis Announce Hart-Scott-Rodino Approval of Collaboration
6. Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen
7. BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture
8. Genzyme Receives European CE Mark for Single-Treatment Synvisc-One(TM)
9. Genzyme Announces FDA Approval of Thyrogen(R) for Use in Thyroid Cancer Ablation
10. Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
11. Genzyme and Sunway to Collaborate on Gene Therapy Program in China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Jan. 22. 2015  Varian Medical Systems (NYSE: VAR ... honored for its commitment to sustainability with inclusion on a ... the highest ranked healthcare equipment company among the Corporate Knights ... World Economic Forum at Davos, Switzerland . ...
(Date:12/25/2014)... The report “Service Quality Management and Telco Customer ... - Global Advancements, Worldwide Forecasts & Analysis (2014-2019)” defines ... forecasting of revenues. , Browse 152 market data ... TOC on “Service Quality Management (SQM) and Telco Customer ...
(Date:12/24/2014)... AUSTIN, Texas , Dec. 24, 2014  Vermillion, ... focused on gynecologic disease, announced today that the ... investors including Oracle Investment Management, Jack W. ... directors. Total proceeds were $10.5 million, before offering ...
(Date:12/24/2014)... (PRWEB) December 23, 2014 GMO corn cases ... Syngenta, are in the process of being consolidated in a ... In Re: Syngenta AG MIR 162 Corn Litigation, MDL No. ... Kansas. , Management of the Syngenta GMO corn multidistrict litigation ...
Breaking Biology Technology:Varian Honored Among World's 100 Most Sustainable Corporations 2Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 2Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 3Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 4Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2
... Inc. (NASDAQ: VSGN ; TSX:VAS) today reported the results ... All dollar amounts referenced herein are in Canadian dollars unless ... cash equivalents totaled $8.6 million, compared with $23.5 million at ... As of January 31, 2009, our cash balance was $8.5 ...
... fast-acting(1) combination treatment option for millions of Americans ... AstraZeneca (NYSE: AZN ) ... Administration (FDA) has approved SYMBICORT (budesonide/formoterol fumarate dihydrate) ... of airflow obstruction in patients with chronic obstructive ...
... Arkion(R) Life Sciences has received a Section 18 Crisis ... effective March 1, 2009. The EPA approval means that ... sweet corn from marauding blackbirds and grackles for the ... applied to corn seed before planting and effectively stops ...
Cached Biology Technology:Vasogen Announces 2008 Year-End Results 2Vasogen Announces 2008 Year-End Results 3Vasogen Announces 2008 Year-End Results 4Vasogen Announces 2008 Year-End Results 5Vasogen Announces 2008 Year-End Results 6Vasogen Announces 2008 Year-End Results 7Vasogen Announces 2008 Year-End Results 8Vasogen Announces 2008 Year-End Results 9Vasogen Announces 2008 Year-End Results 10Vasogen Announces 2008 Year-End Results 11FDA Approves SYMBICORT(R) for Chronic Obstructive Pulmonary Disease (COPD) 2FDA Approves SYMBICORT(R) for Chronic Obstructive Pulmonary Disease (COPD) 3FDA Approves SYMBICORT(R) for Chronic Obstructive Pulmonary Disease (COPD) 4FDA Approves SYMBICORT(R) for Chronic Obstructive Pulmonary Disease (COPD) 5FDA Approves SYMBICORT(R) for Chronic Obstructive Pulmonary Disease (COPD) 6Crisis Exemption Granted to Market Avipel(R) Corn Seed Treatment in Louisiana 2
(Date:12/11/2014)... Research and Markets , ... announced the addition of the "Biometrics Market in ... One major trend emerging in this market is ... utilize more than one characteristic of an individual for ...
(Date:12/10/2014)... YORK , Dec. 8, 2014 You,ve been here before: ... can,t remember your password, site key or the answer to your ... teacher? Today, Hoyos Labs , a digital ... put an end to the frustration that comes with usernames, passwords ...
(Date:12/10/2014)... CIE San Diego has launched an innovative trust network and ... coordination among social service and care providers by enabling them ... grant from the Alliance Healthcare Foundation to expand to organizations ... a "Live Well San Diego" partner on December 11 th ...
Breaking Biology News(10 mins):Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 4
... Four researchers at the U.S. Department of ... have been awarded a total of 65 million ... Gene/P ("Intrepid") supercomputer. The researchers will conduct advanced ... be almost impossible and impractical in the natural ...
... Alexandria, VA Age-related hearing loss (ARHL), one of ... associated with low serum levels of folic acid, according to ... Otolaryngology Head and Neck Surgery . Hearing ... than 28 million Americans between the ages of 60 and ...
... Geo-microbiologists from Arizona State University have solved a ... cyanobacteria, bore their way into limestone, sand grains, ... of carbonate. According to the lead ... the mystery of what is "at the heart ...
Cached Biology News:Argonne scientists awarded supercomputing time to enable scientific breakthroughs 2Argonne scientists awarded supercomputing time to enable scientific breakthroughs 3Argonne scientists awarded supercomputing time to enable scientific breakthroughs 4Mystery dissolves with calcium pump discovery 2Mystery dissolves with calcium pump discovery 3
... weight of 16 kDa. Leptin is a protein ... [1,2]. Leptin is thought to play a key ... In the human, leptin levels are elevated with increasing ... relationship between serum leptin levels and several measures of ...
... the gene supplied by a customer. Mutated DNA ... choice to obtain a library of the mutated ... a desired value within 1-20 mutations per kb. ... be restricted to a desired region of a ...
Request Info...
... endotoxin-free plasmid DNA preparations are prepared ... quantities from 1mg to multi-gram scales. ... customer needs, and glycerol stocks are ... Transformation, clonal selection (Clonal selection includes ...
Biology Products: